Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with an IC50 of 3.55 nM, showing immunomodulatory potential. IRAK4 is a kinase integral to signaling innate immune responses from Toll-like receptors [1]. Zabedosertib also exhibits anti-inflammatory properties against IL-β, LPS, and Imiquimod-induced inflammation [2].
体内研究
Zabedosertib (150 mg/kg, orally, twice) mitigates lung injury and diminishes inflammation in LPS-induced ARDS in BALB/c mice [2].
Zabedosertib inhibits inflammation induced by IL-β (pO., 40-80 mg/kg, once), LPS (pO., 10-40 mg/kg, once), and Imiquimod (pO., 15-150 mg/kg, twice daily for 7 days) [3].
Zabedosertib is characterized by its pharmacokinetic profile in rats [3].
体外研究
Zabedosertib reduces the secretion of inflammatory cytokines such as IL-1, IFN-γ, TNF-α, and IL-17 at 500 nM [2].
搜索
